Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Rhea-AI Summary

Bone Biologics (NASDAQ: BBLG) announced a validated extension of the shelf life for its rhNELL-1 product to 24 months, supported by ongoing stability data and following prior validated 12- and 18-month milestones. The company said this achievement aligns with previously communicated forecasts.

The 24-month shelf life is expected to improve manufacturing efficiency, inventory management, supply-chain flexibility and clinical and commercial readiness as rhNELL-1 advances through development, and the company framed the milestone as supportive of disciplined capital deployment and long-term shareholder value creation.

Key Figures

rhNELL-1 shelf life 24 months Validated shelf life extension milestone for rhNELL-1 product

Prior shelf life 12 months Previously validated rhNELL-1 product shelf-life milestone

Intermediate shelf life 18 months Prior extended rhNELL-1 shelf-life milestone before 24 months

Current share price $1.87 Pre-news price vs 52-week high of $7.74 and low of $1.30

Price change 24h 2.19% Price move in the 24 hours before this announcement

52-week range $1.30–$7.74 Trading range over the last 52 weeks

Q3 2025 net loss $666,737 Net loss for the quarter ended September 30, 2025

Cash balance $6.05 million Cash as of September 30, 2025 per 10-Q filing

Market Reality Check

$1.55 Last Close

Volume Volume 52,114 is 1.54x the 20-day average of 33,943, indicating elevated interest pre-announcement. high

Technical Shares trade below the 200-day MA at 3.23, despite a 24h gain of 2.19%.

Peers on Argus 1 Up

BBLG traded higher while sector peers were mixed, with names like NUWE and VTAK down and VERO and TIVC up. Only TIVC showed strong momentum, suggesting BBLG’s move was more stock-specific than a broad sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Sep 04	CEO shareholder update	Positive	+37.7%	Update on NB1 trial, 18-month shelf life, financing and outlook.
Sep 03	Conference participation	Neutral	-2.4%	Announcement of attendance at H.C. Wainwright investment conference.
Jun 30	Offering closing	Negative	-8.7%	Closing of $5.0M public offering with warrants at $4.00 per share.
Jun 27	Offering pricing	Negative	+10.1%	Pricing of $5.0M public offering and warrants terms disclosed.
Jun 27	Patent filing	Positive	+10.1%	USPTO patent filing for NELL-1 protein bone regeneration technology.

Pattern Detected

BBLG has historically reacted strongly to developmental and financing milestones, with positive clinical/IP updates and some financing events driving large price moves, though one public offering headline saw a negative reaction.

Recent Company History

Over the past six months, BBLG updates have focused on financing, intellectual property, and clinical progress for its NELL-1–based spine fusion program. A June 27, 2025 patent filing and a $5.0M offering both coincided with +10.1% moves, while the June 30, 2025 closing release saw an -8.68% reaction. A September 4, 2025 CEO letter outlining trial progress and extended 18-month protein shelf life led to a +37.68% move. Today’s 24-month shelf-life extension continues that operational progression theme.

Market Pulse Summary

This announcement extends rhNELL-1’s validated shelf life to 24 months, building on prior 12- and 18-month milestones and supporting manufacturing efficiency and commercialization planning. It fits a pattern of operational and clinical progress alongside ongoing losses, with a Q3 2025 net loss of $666,737 and cash of $6.05M. Investors may watch for future clinical readouts, additional manufacturing milestones, and subsequent regulatory updates from the spine fusion program.

Key Terms

orthobiologic medical

"Bone Biologics Corporation ("Bone Biologics" ) ..., a developer of orthobiologic products"

Orthobiologics are medical products made from natural substances—such as blood, bone, or growth factors—used to help heal bones, joints and soft tissues faster or more effectively. For investors, they matter because they represent a growing segment of healthcare that can offer less invasive, often outpatient treatments with potential for recurring sales, intellectual property, and reimbursement shifts that can affect revenue and valuation in companies developing or commercializing these therapies.

spine fusion medical

"a developer of orthobiologic products for spine fusion markets, announces it has received"

Spine fusion is a surgical procedure that joins two or more bones in the spine so they heal into a single, stable unit—think of it as welding together loose links in a chain to stop unwanted movement. Investors care because the procedure drives sales of implants, surgical tools, hospital services, and post-op care; changes in demand, reimbursement rules, or new technologies can affect manufacturers, healthcare providers, and insurers’ revenues and costs.

shelf life technical

"shelf life of its rhNELL-1 product has been extended to 24 months"

Shelf life is the period during which a product, medicine, or other item is expected to remain safe and effective when stored as directed. For investors it matters because shelf life determines how quickly inventory must be sold, how much product may be wasted, and how production and pricing must be managed — like milk in a refrigerator, shorter shelf life forces faster sales or disposal, affecting revenue and costs.

supply-chain technical

"manufacturing efficiency, inventory management, supply-chain flexibility, and clinical"

A supply chain is the network of people, factories, suppliers, transport and warehouses that turn raw materials into finished products and deliver them to customers. For investors it matters because breaks, delays or higher costs anywhere along that chain can reduce a company’s sales, raise expenses or halt production — much like a traffic jam on the only road to a store can stop goods from arriving and cut revenue.

bone growth factor medical

"develop rhNELL-1 as a differentiated bone growth factor designed to promote"

Bone growth factors are natural or engineered proteins that tell bone cells to grow, repair, or form new bone tissue—think of them as a fertilizer that encourages bone to heal or strengthen. They matter to investors because products using these factors can change treatment outcomes for fractures, spinal procedures and joint repairs, affecting clinical success, regulatory approval likelihood, market demand and potential revenue, while also carrying development and safety risks.

bone regeneration medical

"designed to promote controlled, targeted bone regeneration, particularly in hard-to-heal"

Bone regeneration is the process by which the body repairs or replaces damaged bone tissue, sometimes aided by medical treatments like grafts, implants, or biologic drugs. For investors, it matters because successful regeneration technologies can reduce repeat surgeries, shorten recovery times, and create market demand for new medical products—much like a reliable repair crew restoring a broken bridge, improving long-term value and cutting future costs.

AI-generated analysis. Not financial advice.

Milestone advances manufacturing readiness and supports long-term commercialization strategy

BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts.

The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as the Company advances rhNELL-1 through development.

“This milestone reflects continued execution against our development and manufacturing objectives,” stated Jeff Frelick, Bone Biologics Chief Executive Officer. “We believe extending the expected shelf life of rhNELL-1 to 24 months, as previously forecasted, is an important step toward commercialization, improving manufacturing efficiency, supply-chain flexibility, and product readiness. As we advance rhNELL-1 through clinical development, these operational milestones are expected to support disciplined capital deployment and long-term shareholder value creation.”

Bone Biologics continues to develop rhNELL-1 as a differentiated bone growth factor designed to promote controlled, targeted bone regeneration, particularly in hard-to-heal fusion settings.

About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements regarding the expected achievements for the year 2025, timing, implementation, and success of the Company's pilot clinical study, the Company’s development of rhNELL-1 and achievement of operational milestones, the ability of the Company’s lead product candidate NB1 to provide rapid, specific and guided control over bone regeneration and show fusion success in humans, the ability of NB1 to compete in global markets, as well as statements containing the words "anticipate," "may," "believe," “continue,” “design,” "expect," and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contacts

CORE IR
(212) 655-0924
investors@bonebiologics.com

FAQ

What did Bone Biologics announce about rhNELL-1 shelf life on December 23, 2025?

Bone Biologics announced the validated extension of rhNELL-1 shelf life to 24 months, supported by ongoing stability data.

How does the 24-month shelf life affect Bone Biologics (BBLG) manufacturing and supply chain?

The company expects the 24-month shelf life to improve manufacturing efficiency, inventory management, and supply-chain flexibility.

Did Bone Biologics say the 24-month shelf life was forecasted previously?

Yes, the company stated the 24-month shelf life delivers on previously communicated forecasts and follows validated 12- and 18-month milestones.

Will the extended shelf life speed clinical or commercial readiness for rhNELL-1?

The company indicated the extension is expected to enhance clinical and commercial readiness as rhNELL-1 advances through development.

What operational benefits did Bone Biologics cite from the rhNELL-1 shelf-life extension?

Bone Biologics cited benefits including manufacturing efficiency, inventory management, and supply-chain flexibility.

Does the announcement include new financial guidance or revenue figures for BBLG?

No financial guidance, revenue figures, or earnings data were included in the announcement.